Interferon-beta gene therapy using an improved, regulated expression system

a gene therapy and interferon technology, applied in the direction of genetic material ingredients, drug compositions, peptides, etc., can solve the problems of affecting the effect of tm, and reducing the therapeutic effect of tm, so as to maximize the therapeutic effect and minimize the side effects

Inactive Publication Date: 2008-03-27
SCHERING AG
View PDF39 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0011] The present invention provides an improved expression system for the regulated expression of an encoded protein or nucleic acid therapeutic molecule (TM) for use in the treatment of disease, wherein therapeutic efficacy of the TM can be maximized and side effects minimized. In particular, the present invention provides an improved regulated gene expression system, and pharmaceutical compositions and methods thereof for treatment of disease. The encoded TM can be a nucleic acid or protein that provides a therapeutic benefit to a subject having, or susceptible to, a disease. For example, such therapeutic benefit or activity includes, but is not limited to, the amelioration, modulation, diminution, stabilization, or prevention of a disease or a symptom of a disease.

Problems solved by technology

For example, the delivery of bolus protein for the treatment of disease is known to result in adverse side effects including, e.g., those related to infectious and toxic impurities, systemic toxicity, injection-site necrosis, influenza-like symptoms, chills, fever, fatigue, anorexia, and weight loss.
In some cases these events are dose limiting and may lead to cessation of treatment altogether.
However, the administration of protein therapeutics to a patient is known to result in the generation of antibodies against the protein and its rejection by the patient immune system as foreign.
The symptoms and signs of MS can reflect demyelination of neuronal axons in the brain resulting in impaired conductance of neural impulses along the axon.
Thus far, there is no cure for MS and virtually all of the approved treatments target the inflammatory component of the disease.
However, it is known that such IFN protein therapeutics can cause dose-dependent side effects, e.g., flu-like symptoms, nausea, and leukopenia in patients (E. U. Walther (1999) Neurology 53: 1622-27).
These side effects can result in an intolerance to further IFN therapy.
However, most known nucleic acid delivery systems are not suitable for clinical use and do not afford regulated or long-term expression in cells.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Interferon-beta gene therapy using an improved, regulated expression system
  • Interferon-beta gene therapy using an improved, regulated expression system
  • Interferon-beta gene therapy using an improved, regulated expression system

Examples

Experimental program
Comparison scheme
Effect test

example 1

Construction of Vectors for Use in IFN-β or GMCSF Gene Therapy

[0365] A. Plasmid Vectors: The murine IFN-β (mIFN-β) gene from the bacterial expression vector pbSER189 was PCR amplified, with immunoglobulin kappa (IgK) (for protein purification) or mIFN-β (for gene therapy) signal sequence added on the 5′ primer. The PCR products were inserted downstream of the cytomegalovirus (CMV) promoter in the expression vectors pCEP4MWPRE, to generate pGER90 (FIG. 2A) for recombinant protein expression and purification, and pgwiz, to generate pGER101 (FIG. 2B) for gene therapy. [0366] The human IFN-β gene from the bacterial expression vector pbSER178 was PCR amplified by the same procedure as the mIFN-β gene (except with the hIFN signal sequence for the gene therapy vector) and inserted into pCEP4 / WPRE to generate pGER123 (FIG. 2C) for recombinant protein expression and purification, and pgwiz to generate pGER125 (FIG. 2D) for gene therapy. [0367] The construction of plasmid vectors is fully de...

example 2

Pharmacokinetic Studies of IFN-β Gene Delivery

[0371] A. Pharmacokinetic Studies with Human IFN-β: Pharmacokinetic studies were performed in normal mice to compare bolus protein versus gene-based delivery of human IFN-β (hIFN-β). [0372] 1) Human IFN-β1a Protein Phamacokinetic Study: A pharmacokinetic study was carried out in C57BL / 6 mice using bolus injection of recombinant hIFN-β1a delivered either by intramuscular (i.m.) or intravenous (i.v.) injection and using a commercially available ELISA to detect serum levels of hIFN-β. FIG. 3 shows the pharmacokinetic profile of hIFN-β1a protein in serum of mice following a single i.m. or i.v. injection of either 25 ng (1 ug / kg) or 250 ng (10 ug / kg) of hIFN-β1a protein. Following i.v. injection, hIFN-β1a was detected in serum in a dose dependent manner at the first time point (30 min), and was rapidly cleared such that the levels were near the limit of detection (LOD) of the assay (LOD=12.5 pg / ml) by 6 hours. Following i.m. injection of rec...

example 3

Identification and Use of IFN-β Biomarkers for Gene Therapy

[0374] A. Development of mIFN-β Biomarkers: For higher sensitivity in detection of murine IFN-β (mIFN-β) activity in vivo, biomarkers for mIFN-β activity were identified in mice after injection of mIFN-β protein or mIFN-β encoded gene therapy vectors. Biomarkers can be used to follow human IFN-β activity in clinical samples from patients treated with Betaseron (IFN-β 1b) (see e.g., Arnason, B G (1996) Clin Immunol Immunopathol 81: 1-11; Deisenhammer, F et al. (2000) Neurology 54: 2055-60; Knobler, R L et al. (1993) J Interferon Res 13: 333-40.; Kracke, A et al. (2000) Neurology 541: 193-9). One of the primary biomarkers used in the IFN-β clinical studies is MxA (see e.g., Kracke, A et al. (2000) Neurology 541: 193-9; Bertoloto, A et al. (2001) J Imm Meth 256: 141-152) since it is specifically induced by type I IFN's (see e.g., von Wussow, P et al (1990) J Imm 20:2015-19). In the present study, the expression of the MxA mous...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
timeaaaaaaaaaa
timeaaaaaaaaaa
timeaaaaaaaaaa
Login to view more

Abstract

The present invention provides an improved, expression system for the regulated expression of an encoded protein or nucleic acid therapeutic molecule in the cells of a subject, for use in the treatment of disease. In particular, the present invention provides an improved, regulated gene expression system, and pharmaceutical compositions and uses thereof for treatment of disease.

Description

[0001] This application is a continuation-in-part of U.S. patent application Ser. No. 11 / 436,832, filed May 18, 2006, which claims priority of U.S. Provisional Application 60 / 682,762, filed 19 May 2005, both of which are incorporated by reference herein in their entirety.FIELD OF THE INVENTION [0002] The present invention relates to an improved expression system for the regulated expression of an encoded protein or nucleic acid therapeutic molecule, for use in the treatment of disease. In particular, the present invention relates to an improved regulated gene expression system, and pharmaceutical compositions and uses thereof for treatment of disease. BACKGROUND OF THE INVENTION [0003] The delivery of nucleic acids encoding therapeutic molecules (TMs) for treatment of diseases is thought to provide enormous potential as a therapeutic modality over conventional treatment methods. In particular, the delivery of nucleic acids encoding a therapeutic protein, in gene therapy, has the pot...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/70A61P43/00C12N15/87
CPCC07K14/565C07K14/535A61P43/00
Inventor BAUZON, MAXINEHARKINS, RICHARD N.HERMISTON, TERRYKRETSCHMER, PETERSZYMANSKI, PAUL
Owner SCHERING AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap